Company Overview of Opus Bio, Inc.
Opus Bio, Inc. develops and commercializes lentiviral gene delivery products for human diseases for therapeutic, vaccine, and bioproduction applications. The company’s product pipeline includes treatment for chronic lymphocytic leukemia, glioblastoma, melanoma, and hemophilia A; vaccine preclinical programs and vaccine candidates, including virus like particles vaccines that target pandemic and seasonal influenza, Hepatitis C virus infection, and HIV/AIDS; and protein therapeutics that include the production of erythropoietin and factor VIII. It also has various programs on various stem cell types, such as hematopoietic (or blood making) stem cells (HSC) for the treatment of cancer and chron...
910 Clopper Road
Suite 200 South
Gaithersburg, MD 20878
Founded in 2004
Key Executives for Opus Bio, Inc.
Chief Executive Officer and Director
Vice President of Vector Development
Director of Business Planning
Director of Research & Development
Director of Quality Control
Compensation as of Fiscal Year 2014.
Opus Bio, Inc. Key Developments
Juno Therapeutics Partners with Opus Bio
Dec 9 14
Juno Therapeutics, Inc. entered into an agreement to obtain a license from Opus Bio, Inc. (formerly Lentigen Corporation) for a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. Both the companies are based in the US.
Lentigen Corporation Presents at Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop & 1x1 Access Day, Oct-01-2013
Sep 28 13
Lentigen Corporation Presents at Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop & 1x1 Access Day, Oct-01-2013 . Venue: New York, New York, United States.
Lentigen Corporation Receives U.S. Orphan Drug Designation for Novel Gene Therapy for Glioblastoma Multiforme
Feb 13 13
Lentigen Corporation announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug status to P140K methylguanine methyltransferase (MGMT) transduced human CD34 cells (product name: LG631-CD34) for bone marrow protection in the treatment of glioblastoma multiforme. Orphan drug designation qualifies Lentigen for seven years of market exclusivity following marketing approval by the FDA and provides other development-related incentives. LG631-CD34 is currently being evaluated in a NIH grant-funded Phase I clinical trial at University Hospitals (UH) Case Medical Center under the leadership of Stanton Gerson, MD, Director of the Seidman Cancer Center at UH Case Medical Center, Director of the National Center for Regenerative Medicine and Case Comprehensive Cancer Center and Asa, Patricia Shiverick - Jane Shiverick (Tripp) Professor of Hematological Oncology at Case Western Reserve University School of Medicine and Andrew Sloan MD, Associate Professor & Vice-Chairman, Department of Neurological Surgery and the Peter D. Cristal Chair of Neurosurgical Oncology at Case Western Reserve University School of Medicine, Director, Brain Tumor and Neuro-Oncology Center, UH Case Medical Center and a member of the Case Comprehensive Cancer Center.
Similar Private Companies By Industry
Recent Private Companies Transactions